Timothy M. Mayleben, President & CEO at Esperion Therapeutics, Inc. (ESPR), bought 7,500 shares at $34.22 ($259K) on 2019-09-04, disclosed to the SEC on 2019-09-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.42 | 148 | $5K | 1.9% |
| 2 | $34.22 | 4,852 | $166K | 64.1% |
| 3 | $35.25 | 2,500 | $88K | 34.0% |
| Total | $34.55 avg | 7,500 | $259K | 100% |
| Filing → |
| ESPR | BUY | 2019-11-08 | $370K | — | Filing → |
| ESPR | BUY | 2019-08-02 | $198K | — | Filing → |
| ESPR | BUY | 2019-07-01 | $230K | — | Filing → |